Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Stock Short Interest Report for September

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) saw a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 56,600 shares, a drop of 52.6% from the September 15th total of 119,360 shares. Based on an average daily volume of 121,092 shares, the short-interest ratio is presently 0.5 days. Currently, 0.3% of the company’s stock are short sold.

Serina Therapeutics Stock Down 6.0%

SER traded down $0.11 on Wednesday, hitting $1.71. 41,258 shares of the company were exchanged, compared to its average volume of 1,488,652. Serina Therapeutics has a 12 month low of $1.22 and a 12 month high of $5.29. The company has a market cap of $43.43 million, a PE ratio of -0.90 and a beta of 1.19. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.65 and a current ratio of 6.65. The stock’s fifty day moving average is $2.39 and its 200-day moving average is $2.10.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.55) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of Serina Therapeutics in a research report on Thursday, September 10th. One research analyst has rated the stock with a Buy rating. According to MarketBeat.com, Serina Therapeutics has a consensus rating of “Buy” and an average price target of $8.00.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc is a clinical-stage biotechnology company developing medicines designed to provide controlled and sustained drug delivery. The company’s proprietary POZ polymer platform is intended to extend the duration of action of therapeutic compounds, potentially reducing dosing frequency and improving treatment convenience.

Serina’s lead product candidate is SER-252, also known as POZ-apomorphine, an investigational long-acting formulation of apomorphine being developed for patients with Parkinson’s disease.